Study to analyze the clinical and cost impact of complete and incomplete rotavirus (RV) vaccination
Trial overview
Estimation of the clinical impact of complete and incomplete RV vaccination among children less than 5 years of age by determining the incidence of first RV episode.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the clinical impact of complete and incomplete RV vaccination among children less than 5 years of age by calculating the RV-related resource utilization.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the clinical impact of complete and incomplete RV vaccination among children less than 5 years of age by calculating the diarrhea-related resource utilization.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the cost impact of complete and incomplete RV vaccination among children less than 5 years of age by determining the first RV episode costs.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the cost impact of complete and incomplete RV vaccination among children less than 5 years of age by calculating the RV-related healthcare costs.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the cost impact of complete and incomplete RV vaccination among children less than 5 years of age by calculating the diarrhea-related healthcare costs.
Timeframe: During the study period (from January 2000 up to June 2011), an expected average of 1 year and 6 months.
Estimation of the clinical impact of complete and incomplete RV vaccination among children less than 5 years of age by calculating the first diarrhea episode costs.
Timeframe: During the study period (from 2000 up to June 2011).
- Continuously enrolled from birth.
 - (Note: Due to the absence of birth dates in insurance claims data, this inclusion criterion will be met if a child’s year of first enrollment and year of birth are the same. If so, then the date of first enrollment will be used as proxy for date of birth.)
 
- Enrolled in capitation-based health plans.
 - For MarketScan Commercial, residence in states with universal vaccination programs that include the RV vaccine or where RV vaccine inclusion cannot be ascertained (i.e., Alaska, Idaho, Massachusetts, Maine, North Dakota, New Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, Wisconsin, and Wyoming).
 
- Received both medical and pharmacy benefits.
 
Continuously enrolled from birth. (Note: Due to the absence of birth dates in insurance claims data, this inclusion criterion will be met if a child’s year of first enrollment and year of birth are the same. If so, then the date of first enrollment will be used as proxy for date of birth.)
- For MarketScan Commercial, residence in states with universal vaccination programs that include the RV vaccine or where RV vaccine inclusion cannot be ascertained (i.e., Alaska, Idaho, Massachusetts, Maine, North Dakota, New Hampshire, New Mexico, Oregon, Rhode Island, Vermont, Washington, Wisconsin, and Wyoming).
 - Lost to follow-up or had RV prior to 6 weeks of age.
 
Enrolled in capitation-based health plans.
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.